More information about text formats
I agree that the evidence shows no benefit from colchicine in hospitalized patients with covid-19. But I am puzzled by the authors' inclusion of the large, high-quality study by Tardif and colleagues, in high-risk outpatients, as a negative trial. It is true that the benefit of colchicine was not statistically significant when patients who did not have documented covid-19 were included in the analyses. But among patients with positive PCR swabs, those who received colchicine were 30% less likely to develop pneumonia and 25% less likely to wind up hospitalized or dead than those who received placebo - statistically significant in both cases.